Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.54 |
| ▸ | MET | P08581 | 8/20 | 0.54 |
| ▸ | AURKA | O14965 | 7/20 | 0.54 |
| ▸ | TEK | Q02763 | 7/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | LYN | P07948 | 1/20 | 0.39 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.38 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5772930 | 0.83 | KDR (0.54) | KDRMETAURKATEKAURKB | |
| SCHEMBL2748231 | 0.80 | KDR (0.83) | KDRMETAURKATEKAURKB | |
| SCHEMBL4279581 | 0.77 | KDR (0.58) | KDRMETAURKATEKAURKB | |
| SCHEMBL6310268 | 0.77 | KDR (0.53) | KDRMETAURKATEKAURKB | |
| SCHEMBL5772756 | 0.76 | AURKA (0.51) | KDRMETAURKATEKAURKB | |
| SCHEMBL2747018 | 0.75 | KDR (0.71) | KDRMETAURKATEKAURKB | |
| SCHEMBL7880676 | 0.73 | MAPT (0.55) | METMAPTHTTL3MBTL1 | |
| SCHEMBL272878 | 0.72 | KDR (0.55) | KDRMETAURKATEKAURKB | |
| SCHEMBL2710044 | 0.71 | KDR (0.52) | KDRMETAURKATEKAURKB | |
| SCHEMBL2436216 | 0.71 | KDR (0.63) | KDRMETAURKATEKAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660503-A1 | NAPHTHALENE CARBOXAMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS | PFIZER INC. (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050070508-A1 | Napthalene carboxamides and their derivatives useful as new anti-angiogenic agents | AGOURON PHARMACEUTICALS, INC. | 2005-03-31 | — | — | US | disclosed |
| WO-2005021553-A1 | NAPHTHALENE CARBOXAMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS | PFIZER INC. (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070508-A1 | Napthalene carboxamides and their derivatives useful as new anti-angiogenic agents | CCNA1, CCNA2, CCNT1 | KDR 30/4885MET 3202/4885AURKA 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.